UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026766
Receipt number R000030729
Scientific Title Prospective, randomized, open-label, clinical trial comparing the effects of exenatide and sitagliptin on glucose/lipids metabolism and endothelial function in diabetic patients
Date of disclosure of the study information 2017/03/30
Last modified on 2017/03/29 18:31:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective, randomized, open-label, clinical trial comparing the effects of exenatide and sitagliptin on glucose/lipids metabolism and endothelial function in diabetic patients

Acronym

Prospective, randomized, open-label, clinical trial comparing the effects of exenatide and sitagliptin

Scientific Title

Prospective, randomized, open-label, clinical trial comparing the effects of exenatide and sitagliptin on glucose/lipids metabolism and endothelial function in diabetic patients

Scientific Title:Acronym

Prospective, randomized, open-label, clinical trial comparing the effects of exenatide and sitagliptin

Region

Japan


Condition

Condition

Diabetes

Classification by specialty

Medicine in general Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Comparison of exenatide versus sitagliptin on glucose/lipids metabolism and endothelial function in diabetic patients

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Hemoglobin A1C levels, glycoalbumin levels, blood glucose/lipids levels, and flow-mediated vasodilation in forearm
Twelve weeks after administration

Key secondary outcomes

Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria)
Twelve weeks after administration


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of exenatide first, then change to sitagliptin (for 12 weeks each)

Interventions/Control_2

Administration of sitagliptin first, then change to exenatide (for 12 weeks each)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Diabetic patients whose HbA1c levels are greater than 7, despite medical therapy including life style change/medications for at least 8 weeks
2) 20 years of age or older and 75 years of age or younger.
3) Female or Male
4) Outpatients
5) Subjects who gave written informed consent

Key exclusion criteria

Allergy against exenatide /sitagliptin
2) Type I diabetes
3) Secondary diabetes
4) Poor-controlled diabetes (HbA1c>10.0 %)
5) Subjects who takes GLP-1 receptor agonist or DPP4 inhibitor.
6)History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months
7) Either level of aspartate aminotransaminase or alanine aminotransferase exceed three-fold of the normal limits
8) renal insufficiency: serum creatinine>1.3 (male)>1.2(female)
9) Symptomatic (NYHA III or IV) congestive heart failure
10) Malignancies or other diseases with poor prognosis
11) Pregnant
12) Subjects whose doctor in charge do not agree to join the trial

Target sample size

33


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hirotaka Ezaki

Organization

Tokorozawa Herat Center

Division name

Department of Cardiology

Zip code


Address

2-61-11 Kamiarai, Tokorozawa, Saitama, JAPAN

TEL

0429408611

Email

hirotakaezaki@gmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Misa Ito

Organization

Self-Defense Forces Fuji Hospital

Division name

Department of Internal Medicine

Zip code


Address

481-27 Subashiri, Oyamatyo, suntougun, Shizuoka, JAPAN 410-1431

TEL

0550-75-2311

Homepage URL


Email

jumpimjumpim@gmail.com


Sponsor or person

Institute

Tokorozawa Heart Center

Institute

Department

Personal name



Funding Source

Organization

Foundation for Promotion of Defense Medicine

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor

Self-Defense Forces Fuji Hospital
National defense medical college hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

自衛隊富士病院


Other administrative information

Date of disclosure of the study information

2017 Year 03 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2017 Year 03 Month 22 Day

Date of IRB


Anticipated trial start date

2017 Year 03 Month 30 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 03 Month 29 Day

Last modified on

2017 Year 03 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030729


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name